By contrast, FTO suppression inhibited the expression of IL-17RA and alleviated the hepatic inflammation in murine models, which provided a promising target for the therapeutic regimen in the reversal of inflammation-carcinogenesis transformation of HCC. The gene discussed is FTO; the disease is hepatocellular carcinoma.